Bextra “Dear Doctor” letter
Executive Summary
Pfizer/Pharmacia send "Dear Doctor" letter Nov. 13 alerting physicians to new warnings and a contraindication in Bextra labeling against use in patients with demonstrated allergic-type reactions to sulfonamides. The companies first alerted prescribers to the issue in October; revised labeling was approved by FDA Nov. 1 (1"The Pink Sheet" Nov. 11, p. 19)...